Standout Papers

Clinical development of platinum complexes in cancer therapy: an hi... 1987 2026 2000 2013 657
  1. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update (1998)
    David Lebwohl, Renzo Canetta European Journal of Cancer
  2. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 (2004)
    Richard M. Stone, Daniel J. DeAngelo et al. Blood
  3. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. (1987)
    Chao‐Kai Chou, Thomas J. Dull et al. Journal of Biological Chemistry

Immediate Impact

18 by Nobel laureates 28 from Science/Nature 66 standout
Sub-graph 1 of 17

Citing Papers

Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
2022 Standout
mTOR at the nexus of nutrition, growth, ageing and disease
2020 Standout
2 intermediate papers

Works of David Lebwohl being referenced

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
2008
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
1998 Standout

Author Peers

Author Last Decade Papers Cites
David Lebwohl 1126 1783 388 559 31 3.2k
Peter Blume‐Jensen 1249 3245 553 486 25 5.0k
Stefan Hart 1007 1393 267 320 30 2.7k
Terence O’Reilly 1115 1975 664 193 35 3.1k
Ralf A. Hilger 1207 1312 607 407 83 3.1k
Paul Noordhuis 1648 1315 493 338 81 3.3k
Herman Burger 1253 1156 327 519 44 2.6k
Francis J. Giles 761 1009 204 878 51 2.6k
Lance Leopold 1369 1086 429 473 50 2.7k
Franca Stivala 1578 3464 506 514 56 5.3k
Michele McTigue 994 1695 431 196 25 2.9k

All Works

Loading papers...

Rankless by CCL
2026